About: Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 October 2013

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 2013 (uk) im Oktober 2013 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'ochobre de 2013 (ast) scientific article published on 01 October 2013 (en)
publication date	wds:Q58386415-8D2AD58D-A4BC-4F7D-BC67-A937A181C252
publication date	2013-10-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58386415-03DF2F7B-F511-48A4-84F4-A5A92AABB084
language of work or name	English
cites work	wds:Q58386415-1B1D584F-6F58-46DA-814C-38975BA585DD wds:Q58386415-2CF95758-D8CB-4F78-9B87-9FBA515C00ED wds:Q58386415-4761152B-677B-4313-BA8A-0FDB24D3BD2C wds:Q58386415-4ADD9E63-25ED-4E7B-82D3-264D629F6F78 wds:Q58386415-4DDB4715-38BC-4527-8BD7-65576EB685CE wds:Q58386415-4F1487D9-2D2B-4890-908F-1E15C5FC284B wds:Q58386415-56AB670F-E57F-439C-9FE6-7B3F64B632B2 wds:Q58386415-627FE241-E103-44E6-AF52-65233C0616D3 wds:Q58386415-73297616-35EC-47DB-8842-54FEBFDB8DD8 wds:Q58386415-820AC230-D9A3-4103-A8CC-382CE9277182 wds:Q58386415-9577FDC4-9886-4990-9157-508F2D13A10E wds:Q58386415-A9779A55-3719-4A8E-827F-3E2A6C07B9FF wds:Q58386415-AA8A164F-30FF-4024-8173-65BB9F7696B8 wds:Q58386415-D05AB568-5986-4AA7-B3C2-95B71A9A779A wds:Q58386415-D9C373DF-EE8A-4EC8-AB27-C78E6185DA29 wds:Q58386415-E285AE1B-1851-46CB-9DFC-1170D4B82819 wds:Q58386415-E7430E0E-C212-4D8C-8AFB-EBB01EDAE90B wds:Q58386415-EC8BF439-A203-4D9E-A55F-54A15E8DC356 wds:Q58386415-ECECE2EE-F6A7-478A-9356-874259E6190B wds:Q58386415-F0E69A4B-A8AB-4E9D-8010-36DFE6270CA4 wds:Q58386415-F19F898C-A27B-4ED9-8165-DC51E8750E4F wds:Q58386415-F874BE03-08D1-42B2-9C3F-2E965C081E34 wds:Q58386415-FB026EAE-CB8A-4631-B59C-1921373451E2 wds:Q58386415-FD068061-466B-4877-91E9-B865AC6E0990
cites work	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Chemotherapy in malignant pleural mesothelioma. A review. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial. Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma Mesothelin: a new target for immunotherapy From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers Modified RECIST criteria for assessment of response in malignant pleural mesothelioma Toxicity and response criteria of the Eastern Cooperative Oncology Group Advances in malignant mesothelioma Malignant pleural mesothelioma Inflammation-based prognostic indices in malignant pleural mesothelioma. Pentostatin: future directions Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1 Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts
author name string	wds:Q58386415-32812D72-3BC2-4521-B3E4-0AE9679F9BCC wds:Q58386415-51670974-D51A-42C6-A3D5-E9F3103BA638 wds:Q58386415-65DF87FA-3E8C-4A57-A56A-506CE125A866 wds:Q58386415-8F12AD99-B7A3-479A-BF15-B058FB7C647B wds:Q58386415-A0DBCEF3-6064-4F90-B9DD-524BBDB0CFF8 wds:Q58386415-A9DE8F0E-E548-4137-88FF-9C8FFC8407EF wds:Q58386415-B2D5D719-C7A0-4784-87A9-49DB06C7CE66 wds:Q58386415-E92379DE-E2A6-4C82-9576-7E1BDEC4C009 wds:Q58386415-F47D6936-E724-4D97-868D-40D1EE8ABE82
author name string	Daniel H Fowler Ira Pastan Robert J Kreitman Seth M Steinberg James C Reynolds Elad Sharon Alexander Ling Markku M Miettinen Raffit Hassan
rdfs:label	Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression (en) Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression (nl)
skos:prefLabel	Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression (en) Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression (nl)
name	Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression (en) Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression (nl)
author	wds:Q58386415-1BE40879-07BB-4F20-BBF5-39E50736570D wds:Q58386415-3013231F-A9F6-4631-86D8-373EDB802DEC
author	Anish Thomas Andrew C. Miller
title	wds:Q58386415-A1597E0B-C963-4795-B29A-FB8022ED46AD
title	Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression (en)
page(s)	wds:Q58386415-F1B2B4E7-12F5-44A2-AF79-06ACEC729F69
page(s)	208ra147
instance of	wds:Q58386415-632411DF-2954-49BC-BD65-605F75EEC3B9
instance of	scholarly article
PubMed ID	wds:Q58386415-B4F5D01B-6DC9-44FA-9502-91E3B02235AA
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24154601
PubMed ID	24154601
published in	wds:Q58386415-273A3A10-8D25-45F1-BC58-3B15B9211EE0
published in	Science Translational Medicine
issue	wds:Q58386415-3388DF5C-7937-4FE0-A374-36C0C5D566C6
volume	wds:Q58386415-2DFB7E1C-5840-47CF-BBB0-94DA7FBCE4DA
issue	208

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software